| Company Name: |
Xi'an Confluore Biological Technology Co., Ltd.
|
| Tel: |
+86-156-80926068 +86-15680926068 |
| Email: |
1924344760@qq.com |
| Products Intro: |
Product Name:Desthiobiotin-PEG4-Amine
CAS:2306109-91-9
Purity:98% HPLC Package:10MG;25MG;50MG;100MG;1G;5G Remarks:For customers outside China,please use the website:www.confluore.com
|
| Company Name: |
Beijing Jin Ming Biotechnology Co., Ltd.
|
| Tel: |
010-60605840 15801484223; |
| Email: |
psaitong@jm-bio.com |
| Products Intro: |
Product Name:Amine-PEG4-Desthiobiotin
CAS:2306109-91-9
Package:100mg;250mg;500mg Remarks: 试剂级
|
4-Imidazolidinehexanamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-5-methyl-2-oxo-, (4R,5S)- manufacturers
- Desthiobiotin-PEG4-Amine
-
- $0.00 / 100mg
-
2024-04-02
- CAS:2306109-91-9
- Min. Order: 100mg
- Purity: >98.00%
- Supply Ability: 100mg
|
| | 4-Imidazolidinehexanamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-5-methyl-2-oxo-, (4R,5S)- Basic information |
| Product Name: | 4-Imidazolidinehexanamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-5-methyl-2-oxo-, (4R,5S)- | | Synonyms: | 4-Imidazolidinehexanamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-5-methyl-2-oxo-, (4R,5S)- | | CAS: | 2306109-91-9 | | MF: | C20H40N4O6 | | MW: | 432.55 | | EINECS: | | | Product Categories: | | | Mol File: | 2306109-91-9.mol |  |
| | 4-Imidazolidinehexanamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-5-methyl-2-oxo-, (4R,5S)- Chemical Properties |
| Boiling point | 666.0±50.0 °C(Predicted) | | density | 1.078±0.06 g/cm3(Predicted) | | form | Liquid | | pka | 14.93±0.60(Predicted) | | color | Colorless to light yellow |
| | 4-Imidazolidinehexanamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-5-methyl-2-oxo-, (4R,5S)- Usage And Synthesis |
| Biological Activity | Amine-PEG4-Desthiobiotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | 4-Imidazolidinehexanamide, N-(14-amino-3,6,9,12-tetraoxatetradec-1-yl)-5-methyl-2-oxo-, (4R,5S)- Preparation Products And Raw materials |
|